Synthesis and Investigation of Flavanone Derivatives as Potential New Anti-Inflammatory Agents. 2022

Cynthia Sinyeue, and Mariko Matsui, and Michael Oelgemöller, and Frédérique Bregier, and Vincent Chaleix, and Vincent Sol, and Nicolas Lebouvier
Institut des Sciences Exactes et Appliquées (ISEA) EA7484, Campus de Nouville, Université de la Nouvelle Calédonie, Noumea 98851, New Caledonia.

Flavonoids are polyphenols with broad known pharmacological properties. A series of 2,3-dihydroflavanone derivatives were thus synthesized and investigated for their anti-inflammatory activities. The target flavanones were prepared through cyclization of 2'-hydroxychalcone derivatives, the later obtained by Claisen-Schmidt condensation. Since nitric oxide (NO) represents an important inflammatory mediator, the effects of various flavanones on the NO production in the LPS-induced RAW 264.7 macrophage were assessed in vitro using the Griess test. The most active compounds were flavanone (4G), 2'-carboxy-5,7-dimethoxy-flavanone (4F), 4'-bromo-5,7-dimethoxy-flavanone (4D), and 2'-carboxyflavanone (4J), with IC50 values of 0.603, 0.906, 1.030, and 1.830 µg/mL, respectively. In comparison, pinocembrin achieved an IC50 value of 203.60 µg/mL. Thus, the derivatives synthesized in this work had a higher NO inhibition capacity compared to pinocembrin, demonstrating the importance of pharmacomodulation to improve the biological potential of natural molecules. SARs suggested that the use of a carboxyl-group in the meta-position of the B-ring increases biological activity, whereas compounds carrying halogen substituents in the para-position were less active. The addition of methoxy-groups in the meta-position of the A-ring somewhat decreased the activity. This study successfully identified new bioactive flavanones as promising candidates for the development of new anti-inflammatory agents.

UI MeSH Term Description Entries
D008264 Macrophages The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.) Bone Marrow-Derived Macrophages,Monocyte-Derived Macrophages,Macrophage,Macrophages, Monocyte-Derived,Bone Marrow Derived Macrophages,Bone Marrow-Derived Macrophage,Macrophage, Bone Marrow-Derived,Macrophage, Monocyte-Derived,Macrophages, Bone Marrow-Derived,Macrophages, Monocyte Derived,Monocyte Derived Macrophages,Monocyte-Derived Macrophage
D009569 Nitric Oxide A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP. Endogenous Nitrate Vasodilator,Mononitrogen Monoxide,Nitric Oxide, Endothelium-Derived,Nitrogen Monoxide,Endothelium-Derived Nitric Oxide,Monoxide, Mononitrogen,Monoxide, Nitrogen,Nitrate Vasodilator, Endogenous,Nitric Oxide, Endothelium Derived,Oxide, Nitric,Vasodilator, Endogenous Nitrate
D000893 Anti-Inflammatory Agents Substances that reduce or suppress INFLAMMATION. Anti-Inflammatory Agent,Antiinflammatory Agent,Agents, Anti-Inflammatory,Agents, Antiinflammatory,Anti-Inflammatories,Antiinflammatories,Antiinflammatory Agents,Agent, Anti-Inflammatory,Agent, Antiinflammatory,Agents, Anti Inflammatory,Anti Inflammatories,Anti Inflammatory Agent,Anti Inflammatory Agents
D044950 Flavanones A group of FLAVONOIDS characterized with a 4-ketone. 2-Phenyl-Benzopyran-4-Ones,2 Phenyl Benzopyran 4 Ones

Related Publications

Cynthia Sinyeue, and Mariko Matsui, and Michael Oelgemöller, and Frédérique Bregier, and Vincent Chaleix, and Vincent Sol, and Nicolas Lebouvier
February 2005, The Journal of pharmacy and pharmacology,
Cynthia Sinyeue, and Mariko Matsui, and Michael Oelgemöller, and Frédérique Bregier, and Vincent Chaleix, and Vincent Sol, and Nicolas Lebouvier
March 1982, Il Farmaco; edizione scientifica,
Cynthia Sinyeue, and Mariko Matsui, and Michael Oelgemöller, and Frédérique Bregier, and Vincent Chaleix, and Vincent Sol, and Nicolas Lebouvier
January 2017, Current pharmaceutical design,
Cynthia Sinyeue, and Mariko Matsui, and Michael Oelgemöller, and Frédérique Bregier, and Vincent Chaleix, and Vincent Sol, and Nicolas Lebouvier
March 2017, Chemical biology & drug design,
Cynthia Sinyeue, and Mariko Matsui, and Michael Oelgemöller, and Frédérique Bregier, and Vincent Chaleix, and Vincent Sol, and Nicolas Lebouvier
January 2009, Acta poloniae pharmaceutica,
Cynthia Sinyeue, and Mariko Matsui, and Michael Oelgemöller, and Frédérique Bregier, and Vincent Chaleix, and Vincent Sol, and Nicolas Lebouvier
June 2021, Bioorganic chemistry,
Cynthia Sinyeue, and Mariko Matsui, and Michael Oelgemöller, and Frédérique Bregier, and Vincent Chaleix, and Vincent Sol, and Nicolas Lebouvier
June 2020, Bioorganic & medicinal chemistry,
Cynthia Sinyeue, and Mariko Matsui, and Michael Oelgemöller, and Frédérique Bregier, and Vincent Chaleix, and Vincent Sol, and Nicolas Lebouvier
February 2018, European journal of medicinal chemistry,
Cynthia Sinyeue, and Mariko Matsui, and Michael Oelgemöller, and Frédérique Bregier, and Vincent Chaleix, and Vincent Sol, and Nicolas Lebouvier
October 2019, European journal of medicinal chemistry,
Cynthia Sinyeue, and Mariko Matsui, and Michael Oelgemöller, and Frédérique Bregier, and Vincent Chaleix, and Vincent Sol, and Nicolas Lebouvier
January 2017, Iranian journal of pharmaceutical research : IJPR,
Copied contents to your clipboard!